Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.

Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G.

Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86. doi: 10.1007/s00280-008-0845-0. Epub 2008 Oct 22.

2.

Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.

Kang W, Tong JH, Chan AW, Zhao J, Wang S, Dong Y, Sin FM, Yeung S, Cheng AS, Yu J, To K.

Oncol Rep. 2014 Jun;31(6):2579-86. doi: 10.3892/or.2014.3148. Epub 2014 Apr 23.

PMID:
24756820
3.

Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.

Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A, Kasuya K.

J Gastroenterol. 2007 May;42(5):389-94. Epub 2007 May 25.

PMID:
17530364
4.

Overexpression of catalytic subunit M2 in patients with ovarian cancer.

Wang LM, Lu FF, Zhang SY, Yao RY, Xing XM, Wei ZM.

Chin Med J (Engl). 2012 Jun;125(12):2151-6.

PMID:
22884145
5.

The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.

Huang Y, Liu X, Wang YH, Yeh SD, Chen CL, Nelson RA, Chu P, Wilson T, Yen Y.

Urol Oncol. 2014 Jan;32(1):51.e9-19. doi: 10.1016/j.urolonc.2013.08.002.

PMID:
24360663
6.

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.

Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R.

Br J Cancer. 2008 May 20;98(10):1710-5. doi: 10.1038/sj.bjc.6604344. Epub 2008 Apr 15.

7.

Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.

Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y.

Oncol Rep. 2006 May;15(5):1299-304.

PMID:
16596201
8.

Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.

Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M.

Hum Pathol. 2010 Dec;41(12):1742-8. doi: 10.1016/j.humpath.2010.06.001. Epub 2010 Sep 9.

PMID:
20825972
9.
10.

Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.

Iwamoto K, Nakashiro K, Tanaka H, Tokuzen N, Hamakawa H.

Int J Oncol. 2015 May;46(5):1971-7. doi: 10.3892/ijo.2015.2912. Epub 2015 Mar 2.

PMID:
25738429
11.

Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.

Han P, Lin ZR, Xu LH, Zhong Q, Zhu XF, Liang FY, Cai Q, Huang XM, Zeng MS.

Mol Med Rep. 2015 Jul;12(1):401-9. doi: 10.3892/mmr.2015.3360. Epub 2015 Feb 16.

PMID:
25695839
12.

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Farris AB 3rd, Maithel SK.

Cancer. 2013 Jan 15;119(2):454-62. doi: 10.1002/cncr.27739. Epub 2012 Jul 3.

13.

Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.

Zhang M, Wang J, Yao R, Wang L.

Int J Gynecol Cancer. 2013 May;23(4):659-66. doi: 10.1097/IGC.0b013e318287e2b3.

PMID:
23466567
14.

E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.

Fang Z, Gong C, Liu H, Zhang X, Mei L, Song M, Qiu L, Luo S, Zhu Z, Zhang R, Gu H, Chen X.

Biochem Biophys Res Commun. 2015 Aug 21;464(2):407-15. doi: 10.1016/j.bbrc.2015.06.103. Epub 2015 Jun 18.

PMID:
26093293
15.

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.

Cancer Chemother Pharmacol. 2010 Mar;65(4):679-86. doi: 10.1007/s00280-009-1073-y. Epub 2009 Jul 29.

PMID:
19639316
17.

The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.

Su YF, Wu TF, Ko JL, Tsai HT, Tee YT, Chien MH, Chou CH, Lin WL, Low HY, Chou MY, Yang SF, Wang PH.

PLoS One. 2014 Mar 17;9(3):e91644. doi: 10.1371/journal.pone.0091644. eCollection 2014.

18.

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.

Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J.

PLoS One. 2008;3(11):e3695. doi: 10.1371/journal.pone.0003695. Epub 2008 Nov 11.

19.

The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.

Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, Shih J, Hwu EB, Luh F, Yen Y.

Cancer Res. 2003 Oct 15;63(20):6583-94.

20.

Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.

Aird KM, Li H, Xin F, Konstantinopoulos PA, Zhang R.

Cell Cycle. 2014;13(2):199-207. doi: 10.4161/cc.26953. Epub 2013 Oct 29.

Supplemental Content

Support Center